readthroughSign in
CompanyBYSINasdaqFlorham Park, NJ

BeyondSpring Pharmaceuticals Inc.

BeyondSpring develops Plinabulin, a GEF-H1 agonist in late-stage development for multiple cancer indications.

10-QNov 16Latest SEC filing
Nov 12Latest story